Home »

Alios BioPharma to Present Preclinical Data on Its Anti-HCV Nucleotides AL-335 and AL-516 at the 2014 American Association for the Study of Liver Diseases Annual Meeting

Nucleotide Analog AL-335 Demonstrated Synergistic Effects With Other Treatments for HCV, Including Johnson & Johnson–s Anti-HCV Drug Olysio(TM); Compound to Enter Phase 1 Clinical Trials in 4Q/2014 Nucleotide Analog AL-516 Demonstrated Potent Antiviral Activity in Preclinical Studies; to Enter Phase 1 Clinical Trials in 2015

Alios BioPharma Announces Acquisition Agreement With Johnson & Johnson

Agreement Provides Opportunity to Accelerate Development of Antiviral Portfolio and Expand Alios Infectious Disease Drug Discovery Platform

Alios BioPharma Initiates Phase 1 Clinical Trial for Respiratory Syncytial Virus (RSV) Infection

ALS-8176 Is a First-in-Class Nucleoside Analog Targeting the RSV Polymerase and Has Demonstrated Potent Antiviral Activity Against Multiple RSV Strains; Third Compound Advanced to Clinical Trials in the Last 18 Months Discovered Using the Alios Proprietary Nucleoside Analog Library


© 2021 88Finance. All Rights Reserved. Log in

- Copyright by LayerMedia

Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de